SCHEMBL884466

SCHEMBL884466

O=C(c1c(-c2ccccc2)n(C2CCCC[C@H]2O)c(=O)n1Cc1cccc(Oc2ccccc2)c1)N1CCNCC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CHRM3 P20309 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.39
CCR8 P51685 6/20 0.39
MGLL Q99685 1/20 0.39
TPSAB1 Q15661 1/20 0.38
TPSD1 Q9BZJ3 1/20 0.38
TPSG1 Q9NRR2 1/20 0.38
KCNH2 Q12809 2/20 0.38
MAPT P10636 1/20 0.37
FAAH O00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2062692 1.00 KDM4E (0.42) KDM4EALDH1A1LMNAGAASMN1; SMN2
SCHEMBL2062327 1.00 KDM4E (0.42) KDM4EALDH1A1LMNAGAASMN1; SMN2
SCHEMBL2062699 0.93 KMT2A (0.45) KDM4EALDH1A1LMNACHRM3KMT2A
SCHEMBL884945 0.93 KMT2A (0.45) KDM4EALDH1A1LMNACHRM3KMT2A
SCHEMBL885006 0.92 ALDH1A1 (0.37) KDM4EALDH1A1LMNAGAASMN1; SMN2
SCHEMBL2062489 0.90 RXFP1 (0.40) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL884507 0.89 REN (0.39) KDM4EALDH1A1LMNACHRM3KMT2A
SCHEMBL885883 0.89 ALDH1A1 (0.38) KDM4EALDH1A1LMNAGAASMN1; SMN2
SCHEMBL884501 0.88 PTGIR (0.37) KDM4EALDH1A1LMNASMN1; SMN2CHRM3
SCHEMBL886063 0.87 ALDH1A1 (0.35) KDM4EALDH1A1LMNACHRM3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US claimed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US claimed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO claimed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105665-A1 RENIN INHIBITORS REN, ACE, AGT KDM4E 2733/4885ALDH1A1 947/4885LMNA 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.